Xeris Bets on Weekly Shot to Disrupt Thyroid Market

CHICAGO, IL – August 26, 2026

Xeris Biopharma Holdings (Nasdaq: XERS) is preparing to pull back the curtain on what could be its next blockbuster drug, a move that has institutional investors and market analysts watching closely. The company announced it will host a detailed webinar on September 9 for its Phase 3-ready hypothyroidism candidate, XP-8121. While press releases for clinical program updates are routine, this event signals a pivotal moment for a company aiming to disrupt a market serving over 30 million Americans with a therapy that has seen little fundamental innovation in decades.

At the heart of the matter is XP-8121, a once-weekly subcutaneous injection of levothyroxine. If successful, it would represent a monumental shift from the current standard of care: a daily oral pill that, for a significant portion of patients, is a source of constant frustration and inconsistent results. For Xeris, it represents a potential multi-billion-dollar revenue stream, building on the commercial momentum of its existing product portfolio.

A Stubborn Condition, A Vast Market Opportunity

Hypothyroidism is one of the most common endocrine disorders globally. The standard treatment, oral levothyroxine, is effective for many but carries a significant burden. The medication has a narrow therapeutic index and its absorption can be severely hampered by food, coffee, and common supplements like calcium and iron. This forces patients into a strict daily regimen of taking the pill on an empty stomach, typically 30-60 minutes before breakfast, and carefully timing other medications.

This is not just an inconvenience; it's a critical clinical challenge. Up to one-third of treated patients may not be receiving adequate therapy, leading to persistent symptoms like fatigue, weight gain, and depression. Research indicates that between 15% and 20% of patients on oral levothyroxine are considered to have “refractory hypothyroidism,” meaning they fail to achieve stable thyroid hormone levels despite treatment. The causes are split between poor adherence to the complex daily regimen (up to 60% of cases) and gastrointestinal malabsorption issues (up to 40%).

This is the multi-million patient population Xeris has in its sights. “We believe XP-8121 has the potential to address important and persistent challenges faced by patients failing to achieve biochemical control with the current oral therapy due to GI absorption issues,” said John Shannon, Chairman and CEO of Xeris, in a recent statement. The company’s internal estimates peg the addressable market for XP-8121 at 3 to 5 million patients in the U.S. alone, translating to a peak sales opportunity of $1 billion to $3 billion.

The Weekly Shot: A Paradigm Shift in Treatment

The core innovation of XP-8121 lies in its delivery. By using a subcutaneous injection, the drug bypasses the entire gastrointestinal tract, eliminating absorption variability at the source. This is made possible by Xeris’s proprietary XeriSol® technology, which creates stable, non-aqueous liquid formulations ready for injection. The shift from a daily, finicky pill to a simple, once-weekly shot promises two key benefits that form the foundation of its value proposition: consistency and compliance.

For patients with underlying GI conditions like celiac disease, gastritis, or issues following bariatric surgery, XP-8121 could offer a level of predictability that oral therapies simply cannot match. For the broader patient population, a weekly cadence dramatically lowers the risk of non-adherence. “The burden of a daily pill that dictates your morning routine is significant,” one endocrinologist not affiliated with the company noted. “Moving to a weekly administration could fundamentally improve quality of life and, more importantly, clinical outcomes by ensuring a more stable therapeutic level.”

While improved oral formulations like softgels and liquids have entered the market to mitigate some food-related absorption issues, they remain daily therapies. XP-8121 represents a more profound leap, changing not just the formulation but the frequency and reliability of treatment altogether. This positions it as a differentiated, high-value therapeutic rather than just another generic alternative.

Navigating the Gauntlet: Phase 3 and Regulatory Hurdles

With a potential blockbuster on the line, the upcoming Phase 3 trial is the main event. The September 9th webinar is designed to give investors and the medical community a detailed look at the clinical roadmap. Key points of focus will be the trial's design, its primary and secondary endpoints, and the specific patient populations being targeted. Xeris has indicated the trial is expected to enroll approximately 1,000 patients and is slated to begin this year, with a potential market launch around 2030.

Investors will be scrutinizing the trial’s primary endpoints, which will almost certainly revolve around achieving and maintaining normal Thyroid-Stimulating Hormone (TSH) levels. However, secondary endpoints related to patient-reported outcomes—such as symptom relief and quality of life—will be critical for building a compelling case for reimbursement and physician adoption. Demonstrating superiority or even non-inferiority on TSH levels while proving a significant quality-of-life benefit would be a powerful combination.

Adding to investor confidence, Xeris has been shoring up its intellectual property. In December 2025, the U.S. Patent and Trademark Office issued a notice of allowance for a key formulation patent for XP-8121, the second such patent granted. This strengthens the drug's protective moat, a crucial factor in securing its long-term commercial viability against potential competitors.

From Pipeline to Profit: Xeris’s Commercial Blueprint

A promising drug is only as valuable as the company’s ability to bring it to market. Here, Xeris presents a compelling case. It is not a speculative, pre-revenue biotech. The company is a fully integrated commercial organization with three marketed products and a proven track record, particularly in endocrinology.

Its product Recorlev®, for the rare endocrine disorder Cushing’s syndrome, has been a standout performer, with net revenue surging 81% year-over-year to approximately $57 million in the second quarter of 2026. This demonstrates Xeris's ability to successfully launch and grow a specialized product. The company’s total Q2 revenue topped $92 million, and it has tightened its full-year 2026 guidance to a range of $385 million to $390 million.

Crucially, Xeris has achieved adjusted EBITDA positive status, a key milestone that signals a sustainable business model. With $121.75 million in cash and a growing revenue base, the company appears well-capitalized to fund the substantial R&D expenses associated with the XP-8121 Phase 3 program. The established endocrinology sales force that has driven Recorlev's success provides a ready-made commercial engine to launch XP-8121, significantly de-risking the execution phase. As the company prepares to share its vision for the future of hypothyroidism treatment, it stands on a solid foundation of commercial success and financial stability.